As Nycomed officially becomes a wholly owned subsidiary of Takeda Pharmaceutical Company, Takeda has named Frank Morich as the new Nycomed CEO. Morich will also continue in his current position as Executive VP (EVP) of International Operations (Americas/Europe) for Takeda Pharmaceuticals International.
“I look forward to bringing Takeda and Nycomed together to ensure we can achieve enhanced revenue, growth and diversification, while maintaining the strong momentum of both companies,” commented Morich. “The combined company significantly broadens our coverage of the global pharmaceutical market to more than 70 countries, increasing our global Rx sales ranking to 12th and further strengthening our position in the industry.”
Nycomed’s OINDP products include the Alvesco ciclesonide MDI, Omnaris ciclesonide nasal spray, Zymelin/Xymelin xylometazoline nasal spray, and Instanyl intranasal fentanyl. The company has also filed an NDA for a ciclesonide HFA nasal aerosol.
Read the Takeda press release.
